Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Iohexol

Iohexol: 3 brands, 1 generic; first approved Dec 26, 1985; generic available.

Generic available1 exclusivity periodHas discontinued products
Generic status & protection

Generic available: 1 ANDA application approved.

Latest exclusivity ends
Brands (NDA)
3
Generics (ANDA)
1
Listed patents
0
Presentations
15

Brand (NDA) products

Originator applications
Ask AI
  • NDA 01895619889 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    38.8%SOLUTIONINJECTION, ORAL, RECTALRx-
    51.8%SOLUTIONINJECTION, ORAL, RECTALRx-
    64.7%SOLUTIONINJECTION, ORAL, RECTALRxAP
    75.5%SOLUTIONINJECTION, ORALRxAP
    30.2%INJECTABLEINJECTIONRx-
    45.3%INJECTABLEINJECTIONDiscontinued-
    15.1%SOLUTIONURETHRALDiscontinued-
    1.9%SOLUTIONORALRx-
    2.6%SOLUTIONORALRx-
  • NDA 2053832015
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    9.7GM/BOTFOR SOLUTIONORALDiscontinued-
  • NDA 02060819953 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    51.8%SOLUTIONINJECTION, ORAL, RECTALDiscontinued-
    64.7%SOLUTIONINJECTION, ORAL, RECTALRx-
    75.5%SOLUTIONINJECTION, ORALRx-

Generic (ANDA) products (1)

Abbreviated applications
Ask AI
  • IOHEXOL
    ANDA 21773720262 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    64.7%SOLUTIONINJECTION, ORAL, RECTALRxAP
    75.5%SOLUTIONINJECTION, ORALRxAP

Patent & exclusivity timeline

Protection horizon
Ask AI
20262027TodayExclusivity CGT: 2026-07-26Exclusivity CGT
Patent expiryExclusivity endToday

Marketing exclusivity

Hatch-Waxman
Ask AI
  • CGTFDA marketing exclusivity

    4 mo ago

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
Ask AI
First approval
41 yr 6 mo ago
Most recent approval
5 mo ago

Approvals span 1985–2026 across 4 FDA applications.

Brand (NDA) 375%
Generic (ANDA) 125%

Iohexol: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Iohexol

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo